SG11201807228QA - Physical form of a sgr modulator - Google Patents
Physical form of a sgr modulatorInfo
- Publication number
- SG11201807228QA SG11201807228QA SG11201807228QA SG11201807228QA SG11201807228QA SG 11201807228Q A SG11201807228Q A SG 11201807228QA SG 11201807228Q A SG11201807228Q A SG 11201807228QA SG 11201807228Q A SG11201807228Q A SG 11201807228QA SG 11201807228Q A SG11201807228Q A SG 11201807228QA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- pct
- astrazeneca
- english
- march
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Amplifiers (AREA)
- Crystals, And After-Treatments Of Crystals (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property -, Organization IIIMI41101110101011111 HO 11111011101111101010111011101111111110111011# International Bureau .. .... ..Yejd (10) International Publication Number (43) International Publication Date ..... .....1 WO 2017/162747 Al 28 September 2017 (28.09.2017) WIP0 I PCT (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every CO7D 403/12 (2006.01) A61P 11/06 (2006.01) A61K 31/416 (2006.01) A61P 19/02 (2006.01) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, (21) International Application Number: DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/EP2017/056838 HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, (22) International Filing Date: 22 March 2017 (22.03.2017) KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, (25) Filing Language: English RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, (26) Publication Language: English TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: PCT/CN2016/077095 23 March 2016 (23.03.2016) CN (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (71) Applicant: ASTRAZENECA AB [SE/SE]; SE-151 85 Sodertalje (SE). GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, (72) Inventor: CHAOYI, Deng; STA R&D, 288 Fute Zhong Road Waigaoqiao Free Trade Zone, Shanghai, 200131 (CN) . TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, (74) Agent: RACHEL MARIA LOWRY; AstraZeneca UK GW, KM, ML, MR, NE, SN, TD, TG). Milstein Building, Granta Park, Cambridge Cambridge- shire CB21 6GH (GB). Published: — with international search report (Art. 21(3)) 1-1 IN 7r IN ei 1-1 IN 1-1 0 \" (54) Title: PHYSICAL FORM OF A SGR MODULATOR C ) ,.,.. (57) : A crystalline form of 2,2-difluoro-N-[(1R,2S)-3-methyl-1- {[1-(1-methy1-6-oxo-1,6- dihydropyridin-3-y1)-1H-indazol- 5-yl]oxyl - 1 -phenylbutan-2-yl]propanamide (form C), pharmaceutical compositions containing it and its use in therapy.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2016/077095 WO2017161518A1 (en) | 2016-03-23 | 2016-03-23 | New physical form |
| PCT/EP2017/056838 WO2017162747A1 (en) | 2016-03-23 | 2017-03-22 | Physical form of a sgr modulator |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201807228QA true SG11201807228QA (en) | 2018-10-30 |
Family
ID=58398193
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201807228QA SG11201807228QA (en) | 2016-03-23 | 2017-03-22 | Physical form of a sgr modulator |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US10407404B2 (en) |
| EP (1) | EP3433248B1 (en) |
| JP (1) | JP6651648B2 (en) |
| KR (1) | KR102168931B1 (en) |
| CN (1) | CN109415348B (en) |
| AU (1) | AU2017238341A1 (en) |
| CA (1) | CA3016507C (en) |
| CL (1) | CL2018002577A1 (en) |
| ES (1) | ES2926059T3 (en) |
| IL (1) | IL261367A (en) |
| MX (1) | MX2018011288A (en) |
| SG (1) | SG11201807228QA (en) |
| WO (2) | WO2017161518A1 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20230167068A1 (en) * | 2019-12-31 | 2023-06-01 | Medshine Discovery Inc. | Benzopyrazole compound |
| EP4365171A1 (en) * | 2021-06-28 | 2024-05-08 | Medshine Discovery Inc. | Crystal form of triazolopyridine-substituted indazole compound and preparation method therefor |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0611620A2 (en) * | 2005-06-10 | 2009-01-13 | Boehringer Ingelheim Int | glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof |
| TW200815361A (en) | 2005-10-20 | 2008-04-01 | Astrazeneca Ab | Chemical compounds |
| WO2007114763A1 (en) | 2006-03-31 | 2007-10-11 | Astrazeneca Ab | Sulphonamide derivates as modulators of the glucocorticoid receptor |
| EP1878717A1 (en) | 2006-07-14 | 2008-01-16 | Bayer Schering Pharma Aktiengesellschaft | Benzyl amines, a process for their production and their use as anti-inflammatory agents |
| EP1917963A1 (en) | 2006-10-31 | 2008-05-07 | Bayer Schering Pharma Aktiengesellschaft | Cyclic phenyl-substituted indazols, a process for their production and their use as anti-inflammatory agents |
| EP1921067A1 (en) | 2006-11-08 | 2008-05-14 | Bayer Schering Pharma Aktiengesellschaft | Indole and indazole derivatives as anti-inflammatory agents |
| WO2008055709A1 (en) | 2006-11-08 | 2008-05-15 | Bayer Schering Pharma Aktiengesellschaft | Indazole and indole derivatives as anti -inflammatory agents |
| TW200829578A (en) * | 2006-11-23 | 2008-07-16 | Astrazeneca Ab | Chemical compounds 537 |
| JO2754B1 (en) * | 2006-12-21 | 2014-03-15 | استرازينكا ايه بي | Indazolyl amide derivatives for the treatment of glucocorticoid receptor mediated disorders |
| WO2008079073A1 (en) | 2006-12-22 | 2008-07-03 | Astrazeneca Ab | Indazolyl sulphonamide derivatives for the treatment of glucocorticoid receptor mediated disorders |
| EP1958934A1 (en) | 2007-02-16 | 2008-08-20 | Bayer Schering Pharma Aktiengesellschaft | Tetrahydronaphthalenylamides, a process for their production and their use as anti-inflammatory agents |
| EP2062880A1 (en) | 2007-11-22 | 2009-05-27 | Bayer Schering Pharma Aktiengesellschaft | 5-[(3,3,3-Trifluoro-2-hydroxy-1-arylpropyl)amino]-1H-quinolin-2-ones, a process for their production and their use as anti-inflammatory agents |
| EP2072509A1 (en) | 2007-12-18 | 2009-06-24 | Bayer Schering Pharma Aktiengesellschaft | 1-Aryl-1H-quinoline-2-ones: process for their production and their use as anti-inflammatory agents |
| TWI445705B (en) * | 2008-05-20 | 2014-07-21 | Astrazeneca Ab | Phenyl and benzodioxinyl substituted indazoles derivatives |
| EP2149558A1 (en) | 2008-07-21 | 2010-02-03 | Bayer Schering Pharma Aktiengesellschaft | 5-[(3,3,3-Trifluoro-2-hydroxy-1-arylpropyl)amino-1-arylquinolin-2-ones, a process for their production and their use as anti-inflammatory agents |
| US8268820B2 (en) * | 2009-03-26 | 2012-09-18 | Hoffmann-La Roche Inc. | 2,3-diaryl- or heteroaryl-substituted 1,1,1-trifluoro-2-hydroxypropyl compounds |
| JP2014527955A (en) | 2011-06-29 | 2014-10-23 | アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ | Crystal forms of indazolylamide derivatives for the treatment of glucocorticoid-mediated disorders |
| SG11201702225VA (en) * | 2014-09-26 | 2017-04-27 | Astrazeneca Ab | 1-alkyl-6-oxo-1,6-dihydropyridin-3-yl compounds and use as sgrm modulators |
-
2016
- 2016-03-23 WO PCT/CN2016/077095 patent/WO2017161518A1/en active Application Filing
-
2017
- 2017-03-22 AU AU2017238341A patent/AU2017238341A1/en not_active Abandoned
- 2017-03-22 CN CN201780019695.XA patent/CN109415348B/en active Active
- 2017-03-22 WO PCT/EP2017/056838 patent/WO2017162747A1/en active Application Filing
- 2017-03-22 MX MX2018011288A patent/MX2018011288A/en unknown
- 2017-03-22 ES ES17712779T patent/ES2926059T3/en active Active
- 2017-03-22 JP JP2018548920A patent/JP6651648B2/en active Active
- 2017-03-22 KR KR1020187028158A patent/KR102168931B1/en active IP Right Grant
- 2017-03-22 SG SG11201807228QA patent/SG11201807228QA/en unknown
- 2017-03-22 US US16/085,717 patent/US10407404B2/en active Active
- 2017-03-22 EP EP17712779.2A patent/EP3433248B1/en active Active
- 2017-03-22 CA CA3016507A patent/CA3016507C/en active Active
-
2018
- 2018-08-26 IL IL261367A patent/IL261367A/en unknown
- 2018-09-10 CL CL2018002577A patent/CL2018002577A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2017161518A1 (en) | 2017-09-28 |
| US10407404B2 (en) | 2019-09-10 |
| US20190106402A1 (en) | 2019-04-11 |
| JP2019508474A (en) | 2019-03-28 |
| AU2017238341A1 (en) | 2018-09-13 |
| CA3016507C (en) | 2020-10-13 |
| CL2018002577A1 (en) | 2018-12-21 |
| ES2926059T3 (en) | 2022-10-21 |
| CA3016507A1 (en) | 2017-09-28 |
| KR102168931B1 (en) | 2020-10-23 |
| JP6651648B2 (en) | 2020-02-19 |
| IL261367A (en) | 2018-10-31 |
| MX2018011288A (en) | 2019-06-13 |
| CN109415348A (en) | 2019-03-01 |
| KR20180117178A (en) | 2018-10-26 |
| EP3433248B1 (en) | 2022-06-22 |
| CN109415348B (en) | 2021-09-03 |
| WO2017162747A1 (en) | 2017-09-28 |
| EP3433248A1 (en) | 2019-01-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201900135YA (en) | N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors | |
| SG11201804915RA (en) | Methods for treating huntington's disease | |
| SG11201808990QA (en) | Compositions for topical application of compounds | |
| SG11201901747VA (en) | Inhibitors of cellular metabolic processes | |
| SG11201907034PA (en) | Methods of treating influenza | |
| SG11201804934PA (en) | Novel Compounds | |
| SG11201805300QA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201810423XA (en) | Pd-1 / pd-l1 inhibitors for cancer treatment | |
| SG11201907840RA (en) | Fused imidazo-piperidine jak inhibitors | |
| SG11201804901WA (en) | Compounds for the treatment of cancer and inflammatory disease | |
| SG11201907650RA (en) | Personal therapy and exercise monitoring and oversight devices, systems, and related methods | |
| SG11201807784SA (en) | 3-desoxy derivative and pharmaceutical compositions thereof | |
| SG11201907023UA (en) | Method of reducing neutropenia | |
| SG11201909155VA (en) | Ask1 inhibitor compounds and uses thereof | |
| SG11201500005SA (en) | Pyrimidine pyrazolyl derivatives | |
| SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201809499UA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201900551WA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201900546UA (en) | Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201810352XA (en) | New antibacterial compounds | |
| SG11201906222WA (en) | Jak1 selective inhibitors | |
| SG11201901063SA (en) | Therapeutic agents for neurodegenerative diseases | |
| SG11201810143PA (en) | Exon skipping oligomers for muscular dystrophy | |
| SG11201809702SA (en) | Benzenesulfonamide compounds and their use as therapeutic agents |